Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell–T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory–induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell–based immunotherapies.
Christopher A. Klebanoff, Christopher D. Scott, Anthony J. Leonardi, Tori N. Yamamoto, Anthony C. Cruz, Claudia Ouyang, Madhu Ramaswamy, Rahul Roychoudhuri, Yun Ji, Robert L. Eil, Madhusudhanan Sukumar, Joseph G. Crompton, Douglas C. Palmer, Zachary A. Borman, David Clever, Stacy K. Thomas, Shashankkumar Patel, Zhiya Yu, Pawel Muranski, Hui Liu, Ena Wang, Francesco M. Marincola, Alena Gros, Luca Gattinoni, Steven A. Rosenberg, Richard M. Siegel, Nicholas P. Restifo
Title and authors | Publication | Year |
---|---|---|
Antigen-specific B-cell depletion for precision therapy of mucosal pemphigus vulgaris
Jinmin Lee, Daniel K. Lundgren, Xuming Mao, Silvio Manfredo-Vieira, Selene Nunez-Cruz, Erik F. Williams, Charles-Antoine Assenmacher, Enrico Radaelli, Sangwook Oh, Baomei Wang, Christoph T. Ellebrecht, Joseph A. Fraietta, Michael C. Miloneǂ, Aimee S. Payne |
Journal of Clinical Investigation | 2020 |
Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells
CM Mousset, W Hobo, A de Ligt, S Baardman, NP Schaap, JH Jansen, AB van der Waart, H Dolstra |
Cancer Immunology, Immunotherapy | 2020 |
Stem Cell-Derived Viral Antigen-Specific T Cells Suppress HBV Replication through Production of IFN-γ and TNF-⍺
M Haque, F Lei, X Xiong, Y Ren, A Kumar, JK Das, X Ren, D Fang, P de Figueiredo, JM Yang, J Song |
iScience | 2020 |
Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies
RC Nelson, V Fellowes, P Jin, H Liu, SL Highfill, J Ren, J Szymanski, WA Flegel, DF Stroncek |
Transfusion | 2020 |
Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours
E Chruściel, Z Urban-Wójciuk, Ł Arcimowicz, M Kurkowiak, J Kowalski, M Gliwiński, T Marjański, W Rzyman, W Biernat, R Dziadziuszko, C Montesano, R Bernardini, N Marek-Trzonkowska |
Cancers | 2020 |
Engineering T cells for immunotherapy of primary human hepatocellular carcinoma
LD Galva, L Cai, Y Shao, Y He |
Journal of genetics and genomics = Yi chuan xue bao | 2020 |
Development of CAR-T cell therapy for B-ALL using a point-of-care approach
L de Macedo Abdo, LR Barros, MS Viegas, LV Marques, P de Sousa Ferreira, L Chicaybam, MH Bonamino |
OncoImmunology | 2020 |
Stress Management: Death Receptor Signalling and Cross-Talks with the Unfolded Protein Response in Cancer
E Lafont |
Cancers | 2020 |
Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
A Gavriil, M Barisa, E Halliwell, J Anderson |
Cancers | 2020 |
Epigenetic mechanisms underlying HIV-Infection induced susceptibility of CD4+ T cells to enhanced activation-induced FasL expression and cell death
SS Ghare, PM Chilton, AV Rao, S Joshi-Barve, P Peyrani, AR Vega, CJ McClain, K Bryant, RL Cook, M Freiberg, S Barve |
Journal of acquired immune deficiency syndromes (1999) | 2020 |
Memory T cells: strategies for optimizing tumor immunotherapy
Q Liu, Z Sun, L Chen |
Protein & Cell | 2020 |
Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy
T Mika, S Ladigan-Badura, A Maghnouj, B Mustafa, S Klein-Scory, A Baraniskin, S Döhring, I Fuchs, S Ehl, SA Hahn, R Schroers |
Frontiers in Oncology | 2020 |
Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 + T cells
CJ Dwyer, DC Arhontoulis, GO Rivera, HM Knochelmann, AS Smith, MM Wyatt, MP Rubinstein, C Atkinson, JE Thaxton, DM Neskey, CM Paulos |
European Journal of Immunology | 2020 |
Re-defining T-Cell Exhaustion: Subset, Function, and Regulation
SJ Im, SJ Ha |
Immune Network | 2020 |
Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy
M Feist, Z Zhu, E Dai, C Ma, Z Liu, E Giehl, R Ravindranathan, SJ Kowalsky, N Obermajer, US Kammula, AJ Lee, MT Lotze, ZS Guo, DL Bartlett |
Cancer Gene Therapy | 2020 |
Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19
AJ Leonardi, RB Proenca |
Frontiers in immunology | 2020 |
Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
S Arcangeli, L Falcone, B Camisa, FD Girardi, M Biondi, F Giglio, F Ciceri, C Bonini, A Bondanza, M Casucci |
Frontiers in immunology | 2020 |
A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS
ME Maccari, S Fuchs, P Kury, G Andrieux, S Völkl, B Bengsch, MR Lorenz, M Heeg, J Rohr, S Jägle, CN Castro, M Groß, U Warthorst, C König, I Fuchs, C Speckmann, J Thalhammer, FG Kapp, MG Seidel, G Dückers, S Schönberger, C Schütz, M Führer, R Kobbe, D Holzinger, C Klemann, P Smisek, S Owens, G Horneff, R Kolb, N Naumann-Bartsch, M Miano, J Staniek, M Rizzi, T Kalina, P Schneider, A Erxleben, R Backofen, A Ekici, CM Niemeyer, K Warnatz, B Grimbacher, H Eibel, A Mackensen, AP Frei, K Schwarz, M Boerries, S Ehl, A Rensing-Ehl |
Journal of Experimental Medicine | 2020 |
Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases
M Kroemer, C Turco, L Spehner, J Viot, I Idirène, A Bouard, E Renaude, M Deschamps, Y Godet, O Adotévi, S Limat, B Heyd, M Jary, R Loyon, C Borg |
Journal for ImmunoTherapy of Cancer | 2020 |
Modes of Communication between T Cells and Relevance for Immune Responses
L Uhl, A Gérard |
International journal of molecular sciences | 2020 |
Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy
Y Yang, J Zhou, C Cao, P Cai, X Wang, C Chang, J Wang, Q Zhang |
Translational cancer research | 2020 |